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Abstract:
Introduction:
Although the local adverse effects of ophthalmic drugs, including allergic reactions, are well recognized, less is known about the
systemic side- effects of eye drops, especially during pregnancy, breast-feeding and early childhood. Ophthalmologists should also
be aware of unusual, in some cases even life-threatening, effects of commonly used eye drops.
Conclusion:
This brief review outlines the routes of systemic absorption and the kinetics of active components present in eye drops, and identifies
the clinically relevant systemic adverse effects.
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1. INTRODUCTION
Local  therapy,  as  administered  in  dermatology,  in  lung,  ear  and  nose  diseases  as  well  as  in  ophthalmology,  is
assumed to exert its effects in the organ treated, but can in fact also evoke systemic, mainly harmful effects if the drug
is  absorbed  into  the  circulation.  It  is  nearly  fifty  years  ago  since  the  first  case  reports  of  acute  elevation  of  blood
pressure in pediatric patients after cyclopentolate- [1] or phenylephrine- [2, 3] containing eye drops were published. The
increase  in  blood  pressure  seen  in  low  birth  weight  infants  was  apparently  attributable  to  large  doses/high  drug
concentrations in the eye drops used. The mucosal epithelium in the mucous membranes of the conjunctiva and nose is
readily permeable to drugs, allowing them to gain access to the systemic circulation without being subjected to first-
pass metabolism in the liver. Aged patients are another at- risk population; timolol for example has exerted systemic
adverse effects causing bradycardia, a fall in blood pressure and bronchoconstriction [4, 5]. Many of the adverse effects
experienced by  the  elderly  are  associated  with  polypharmacy and the  simultaneous  treatment  of  different  diseases.
Pregnant  women or  nursing  mothers  comprise  another  group  of  at-  risk  patients  with  respect  to  ophthalmic  drugs.
Recently, more has been learned regarding the systemic effects of ophthalmic drugs and it is now appreciated that they
may not merely be distressing but in some cases even life threatening. We herein provide a short overview of what is
known about drug absorption and transport from the eye to the circulation and subsequently to various organs in the
body.
1.1. Kinetics of Drugs in the Eye and Their Transport from the Eye
The  pharmacokinetic  aspects  of  locally  administered  ophthalmic  drugs  display  many  special  characteristics  in
comparison to other routes of administration. This topic has in fact been thoroughly discussed in a recent review [6].  
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The size of the drop as well as the vehicle  used  and  the  lipophilicity/hydrophilicity  of  the  active  compound,  i.e. its
physicochemical properties, as well as its concentration in the preparation, are the main determining factors. Lipophilic
drugs  are  absorbed  well  through  the  cornea,  whereas  both  lipophilic  and  hydrophilic  compounds  are  well  able  to
penetrate  through  the  conjunctiva  and  sclera.  The  vitreous  humor  can  transport  drugs  via  the  blood-retinal  barrier,
lipophilic compounds being more readily transported. There is also a route out of the vitreous humor via the anterior
chamber, through which both hydrophilic and lipophilic drugs can be excreted [6, 7]. When eye drops are dispensed
onto the surface of the eye, they remain there for only a short time even when ophthalmic ointments are used. If the
patient presses the medial eye-nose corner (so-called puncta compression), this can retard the diffusion of the drug into
the lacrimal drainage. It has been estimated that the ocular bioavailability of the active compound in eye drops is very
poor,  a  mere  5  -10%.  Other  factors  can  contribute  to  their  low  bioavailability,  namely  binding  to  proteins  and
metabolizing enzymes in the lacrimal fluid, the thickness of the corneal surface and lacrimal film as well as conjunctival
hyperemia [6].
The precise  role  of  the  influx  transporters,  e.g.  organic  cations  and peptides,  can  influence  penetration  through
membranes,  depending on the chemical nature of the particular agent in question [8].  Furthermore, the presence of
drug- metabolizing CYP enzymes in the ocular tissues can be of importance e.g. in the case of timolol [9]. There are
also other enzymes, e.g. esterases, in the eye; which are important in that they metabolize prodrugs into their active
form,  as  for  example  dipivefrin  to  adrenaline,  latanoprost  to  prostaglandin  F2alpha [6].  Orally  administered drugs,
which inhibit various drug- metabolizing CYP enzymes, can retard the metabolism of ophthalmic agents after their
absorption into the eye, and on the other hand, can cause systemic adverse interactions after the topical drug has gained
access to the circulation [10]. For this reason, patients who are poor metabolizers of CYP2D6 or are receiving drug
treatment with potent inhibitors of this enzyme (e.g. paroxetine, fluoxetine or verapamil) are at- risk of adverse cardiac
effects (e.g. bradycardia) when using timolol or betaxolol eye medication [11].
Drugs applied in the “cul-de-sac” encounter many drug- metabolizing enzymes existing in the ocular tissues and
fluids. Some metabolism of the drugs can occur already in the ocular tissues. Furthermore, the proportion of the drug
which is absorbed into the mucosal membrane of the nose can bypass the first- pass metabolic processes in the liver and
reach its target tissues more readily than if given orally. It has been estimated that up to 80% of a drug applied onto the
conjunctival sac may diffuse into the systemic circulation via the highly vascularized nasopharyngeal route [6]. Other
minor but nonetheless important routes of systemic absorption are the conjunctiva (increased with hyperemic drugs),
lacrimal drainage, the skin of the cheek and eyelids, aqueous humor and even the inner parts of the eye.
Intravitreal  injection  is  a  special  form  of  ocular  application  of  drugs,  often  utilized  for  more  recent  biological
preparations [12]. In this case, these compounds are removed either across the vitreous body in the posterior chamber
and then onwards to the aqueous and uveal circulation across the blood – ocular barrier passively or by exploiting active
transporter systems [6, 13]. Interestingly, it has been speculated that intravitreal anti-VEGF drugs could cause systemic
thromboembolic adverse events [14], and thus are usually clinically contraindicated during the first year after cardiac or
brain ischemic events. More evidence will, however, be needed to confirm these suspicions.
In view of the possibility that ophthalmic drugs can exert systemic adverse reactions, we surveyed the Finnish Drug
Manual for Physicians (Pharmaca Fennica) to identify the most common systemic adverse effects of ocular drugs; these
are summarized in Tables (1 and 2).
Table  1.  Ocular  drugs.  Reported  systemic  contraindications  and  systemic  adverse  effects  of  antiglaucoma  medications.
Contraindication involves hypersensitivity to ingredients or adjuvants. Reference: Finnish Pharmaca Fennica.
ANTIGLAUCOMA
MEDICATIONS
SYSTEMIC CONTRAINDICATIONS REPORTED SYSTEMIC ADVERSE EFFECTS (USUALLY RARE)
Alpha-agonists
Apraclonidine MAO inhibitors, children Dry mouth, drowsiness, tachyarrhythmias, depressio, nausea,
vasodilatation, taste disturbances, dyspnea, rhinorrea, constipation,
dermatitis, skin rash
Brimonidine Nursing mothers, infants, MAO inhibitors,
tricyclic antidepressants, with caution in
depression
Dry mouth, drowsiness, dizziness, tachyarrhythmias, headache, arterial
hypo / hypertension, heart failure, taste disturbances, symptoms in upper
airways, gastrointestinal-symptoms, skin rash
Beta-blockers
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ANTIGLAUCOMA
MEDICATIONS
SYSTEMIC CONTRAINDICATIONS REPORTED SYSTEMIC ADVERSE EFFECTS (USUALLY RARE)
Betaxolol (selective) Asthma, emphysema, COPD, congestive
heart failure, bradycardia, sick sinus
syndrome, AV block (II,III)
Milder but similar systemic side- effects as timolol
Timolol (non- selective) Asthma, emphysema, COPD, congestive
heart failure, bradycardia, sick sinus
syndrome, AV block (II,III)
Usually well tolerated, bradycardia, hypotensio, headache, dizziness,
depression, hallucinations, anxiety, mental confusion, hair loss, broncho-
obstruction, AV-block, urticaria, hypoglycemia, myastenia gravis, hair
loss, anaphylaxis, insomnia, nausea, dry mouth, cough, lowered libido,
muscle pain
Carbon anhydrase
inhibitors
Sulfonamide allergy, metabolic acidosis,
with caution in the presence of
hypocalcemia, hyponatremia
Acetazoleamide systemic Renal acidosis, Addison's disease, severe
renal/liver dysfunction
Paresthesia, malaise, fatigue, gastrointestinal disturbances, renal disorders,
blood dyscrasias, metabolic acidosis, diarrhea/constipation, fever,
urticaria, confusion, sleepiness, depression, gout, renal stones, taste
disturbances
Brinzolamide Severe renal insufficiency, hyperchloremic
acidosis
Taste disturbances, nasopharyngeal infections, changes in red blood cell
count and in blood chloride concentrations, depression, apathy, lowered
libido, nightmares, insomnia, amnesia, dizziness, tinnitus, palpitations,
angina pectoris, respiratory and asthma symptoms, epistaxis, sore throat,
cough, gastrointestinal disturbances, eczema, muscle pain, malaise
Dorzolamide Severe renal insufficiency, hyperchloremic
acidosis
Headache, dizziness, paresthesias, epistaxis, malaise, dry mouth, renal
stones, fatigue, eczema, itchiness, Stevens-Johnson syndrome
Cholinergics
Pilocarpine None Headache, vertigo, malaise, asthma symptoms
Prostaglandin analogues Skin pigmentation
Bimatoprost None Headache, tachycardia, hypertension, nausea, skin rash, dizziness,
abnormal liver values
Latanoprost None Headache, tachycardia, skin rash, dizziness, exacerbated asthma
symptoms, muscle and joint pain
Tafluprost None Headache, hypertension, exacerbated asthma symptoms, asthenia,
abnormal liver values
Travoprost None Taste disturbances, dizziness, visual field defects, headache, tachy /
bradycardia, hypo/ hypertension, asthma, difficulty in breathing, cough,
dysphonia, sore throat, dermatitis, changes in hair structures,
musculoscleletal pain, weakness, malaise
Table  2.  Ocular  drugs.  Reported  systemic  contraindications  and  systemic  adverse  effects  of  other  ophthalmic  drugs.
Contraindication involves hypersensitivity to ingredients or adjuvants. Reference: Finnish Pharmaca Fennica.
ANTIHISTAMINICS SYSTEMIC
CONTRAINDICATIONS
REPORTED SYSTEMIC ADVERSE EFFECTS
(USUALLY RARE)
Azelastine None Eczema, itching, disturbance to taste
Emedastine None Headache, disturbance to taste, eczema, weird dreams
Ketotifen None Headache, eczema, dry mouth, drowsiness
Levocabastine None Angioneurotic edema, urticaria, headache
Olopatadine None Rhinitis, headache, dysgeusia, eczema, fatigue
ANTIMICROBIALS
Aciclovir None None
Chloramphenicol None Aplastic anemia, agranulosytosis, peripheric neuropathy
Fucidinic acid None Eczema, itching
Levofloxasin None Eczema, headache, rhinitis
Ofloxacin None Eczema, headache, rhinitis
Tobramycin None Headache, laryngospasm
INHIBITORS OF HISTAMINE RELEASE
Lodoxamide None Headache, vertigo, fatigue, malaise, eczema, rhinitis
Cromoglycate None None
(Table 1) contd.....
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LOCAL ANESTHETICS
Oxybuprocaine None Bradycardia, hypotensio, vertigo, tremor
MOISTENING PREPARATIONS None None
MYDRIATICS
Atropine None Dry mouth, skin redness, tachycardia, gastrointestinal
symptoms
Cyclopentolate None Fatigue, confusion, anxiety, hallucinations
Phenylephrine None Hypertension, reflectory bradycardia, tachycardia,
palpitations, headache, tremor, sweating
Scopolamine None Dry mouth, constipation, confusion, anxiety, drowsiness,
hallucinations
Tropicamide None Dry mouth, constipation, confusion, anxiety, drowsiness,
hallucinations
NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS
Bromfenac Acetylsalicylic acid (ASA) sensitivity Epistaxis, cough, rhinitis, asthma symptoms, face swelling
Diclofenac Acetylsalicylic acid (ASA) sensitivity Itching, cough, rhinitis
Ketorolac Acetylsalicylic acid (ASA) sensitivity Headache, bronchospasm, asthma symptoms
Nepafenac Acetylsalicylic acid (ASA) sensitivity Headache, malaise, cutis laxa
STEROIDS
Dexamethasone None None
Fluorometholone None Hypercorticoidism
Prednisolone None Headache, itching, tastedisturbances
VASOCONSTRICTORS
Tetrahydrozoline None Hypertensio, palpitatio, sweating, anxiety, fatigue
VEGF INHIBITORS
Aflibersept None Theoretical risk of arterial thromboembolic attacks
Ranibizumab None Headache, nasopharyngitis, joint pain, anemia, anxiety,
cough, malaise, theoretical risk of arterial thromboembolic
attacks
In the following sections we will present more detailed data on four especially at-risk clinical groups (children,
pregnant and nursing women and elderly subjects), as well as some rare clinical problems.
1.2. Children
Newborns and infants require special attention by reason of their anatomical differences in comparison to adult
eyes. The absorbing membranes are thin and drug penetration can thus be rapid, the tear volume is small, meaning that
the drug concentration in the eye is higher than in adults. Young children up to school age need “smaller” drops and/or
lower concentrations of ophthalmic preparations [6, 15], but these are unfortunately rarely available. Similarly to the
situation with other medicines, few kinetic or therapeutic studies of ophthalmic agents in the case of children have been
published; those in the literature often comprise case reports depicting toxicity. Mydriatic drugs, e.g. cyclopentolate,
which are widely used in the ophthalmological examination of pediatric patients, can trigger to respiratory distress [16],
cyclopentolate  and  phenylephrine  can  evoke  myoclonic  seizures  [17,  18].  Furthermore,  they  may  cause  skin  rash,
tachycardia, feeding problems, discomfort, apnea, gastric dilatation and ileus. Ozgun and associates 2014 [19] reported
a lethal case of diffuse necrotizing enterocolitis after topical application of drops containing 0.5% cyclopentolate and
1.25% phenylephrine. Phenylephrine, on the other hand, can cause hypertension, ECG changes and elevation in cardiac
troponin Ic  [20].  However,  the case report  in  question seems to be exception,  since a  systematic  review and meta-
analysis  [21]  found  no  evidence  that  phenylephrine  2.5% evoked  clinically  relevant  changes  in  heart  rate,  and  the
reported  elevation  in  blood  pressure  was  short  lasting.  In  clinical  practice,  mydriatic  eye  drops  (tropicamide  and
phenylephrine 2.5%) are widely dispensed for small infants, for example to investigate premature retinopathy.
Anti-glaucoma drugs are used in the treatment of childhood glaucoma; however, none of the drug concerned has
been approved by the regulatory agencies for administration to children, i.e. they are being used on an off-label basis.
Once- a -day application of timolol gel for some time now has been the first  choice in pediatric glaucoma. Second
choice is a combination of timolol once a day and a carbonic anhydrase inhibitor (CAI) twice a day. Both medications
(Table 2) contd.....
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are effective and well tolerated, though in theory, timolol drops can cause severe bronchoconstriction and CAI may
induce metabolic acidosis [22, 23]. Betaxolol solution is a selective beta-1 antagonist, and thus involves a lower risk
than  timolol  of  triggering  pulmonary  side-  effects  [23].  The  safety  profile  of  prostaglandin  analogues  seems  to  be
excellent also in children, although they are not recommended for use in infants under one year of age due to poor
knowledge of their adverse effects. The kinetics and systemic effects of latanoprost have been evaluated in one study
using once daily treatment;  it  was concluded that  systemic exposure was more marked in younger children than in
adolescents and adults. The drug was rapidly eliminated in all age groups, and no clinically significant adverse effects
were reported in any [24]. According to several reports, anti-glaucoma therapy with alpha2-agonists (e.g. brimonidine)
is contraindicated for children younger than 2 years of age [23, 25 - 27], there is even one claim that these drugs should
not  be  administered  to  children  younger  than  6  years  and  weighing  less  than  20  kg  [23].  The  reason  for  these
recommendations  is  that  alpha2-agonists  such  as  brimonidine  have  evoked  severe  central  nervous  depression,
sleepiness,  lethargia,  hypotonia,  hypothermia,  bradycardia  and  apnea  in  infants  [23  -  25,  28].
Chloramphenicol is one of the most widely used antibiotic ophthalmic preparations for the treatment of bacterial
conjunctivitis in infants. Allergic reactions are possible. There are some anecdotal, poorly defined, cases in the older
literature of chloramphenicol-induced bone-marrow hypoplasia and blood dyscrasias [29, 30, 31]. It is possible that
there had been previous chloramphenicol exposure in the form of oral therapy and the side- effects attributed to the eye
drops were thus in fact a secondary immunological reaction. Orally administered chloramphenicol is contraindicated in
neonates  due  to  the  life-  threatening  “gray  baby  syndrome”  [32].  Other  local  ophthalmic  antibiotics  such  as
fluoroquinolones  are  usually  taken  to  be  contraindicated  for  infants  under  one  year  of  age  because  of  the  lack  of
knowledge of their potential side effects.
Corticosteroid  eyedrops  are  valuable  in  the  treatment  of  intraocular  endogenous  inflammation  such  as  juvenile
rheumatoid  arthritis  associated  eye  diseases  and  other  uveitic  conditions.  A  few  reports  have  been  published  on
significant systemic adverse effects of corticosteroid drops. When corticosteroids are absorbed via the ocular or nasal
mucous membranes, they do not undergo first-pass metabolism in the liver. Even locally administered steroids may
cause adrenal suppression after prolonged administration, especially in children [33]. There are conflicting opinions on
the ophthalmic use of corticosteroids in small children and their effects on growth. Wolthers (2011) utilized a novel
method, knemometry; he reported that two weeks´ treatment with the synthetic corticosteroid, fluorometholone, did
transiently suppress growth, but this had no impact on height gain during the following year [34].
1.3. Pregnant and Nursing Women
There are limited data on this topic as prospective and randomized clinical trials are subject to ethical and legal
constraints  in  this  patient  population [35].  The smallest  dose/concentration and shortest  possible  exposure time are
recommended in these patients. As a general rule, drugs should (if possible) be especially avoided in the first trimester
during the time of organogenesis [36]. Razeghinejad and collagues stated that according to the FDA classification, anti-
glaucoma drugs should be categorized as class C [37], i.e. ”risk for the fetus cannot be ruled out”. The exceptions are
brimonidine and nonspecific adrenergic agonists, which have been categorized as class B “no evidence of risk”. The
FDA group C also includes tobramycin, ciprofloxacin, phenylephrine, latanoprost and corticosteroids.
In patients with severe high-pressure glaucoma e.g. secondary glaucoma due to uveitis, it is essential to administer
anti-glaucoma  drugs  even  during  pregnancy.  In  these  cases  it  is  important  to  ensure  that  the  patient  presses  her
nasolacrimal puncta for a couple of minutes after each drop. In addition, laser treatment of the trabecular meshwork is
preferable as this obviates the need for drug therapy. The first trimester of pregnancy, i.e. the period of organogenesis,
should be kept as a drug-free period [38]. Beta-blockers should be avoided due to their hazardous effects on the fetus
such as retardation of growth, cardiac conduction disorder, even teratogenic effects.
Beta-blockers are actively excreted into breast milk and can be harmful for the newborn. These infants should be
closely monitored for signs of apnea and bradycardia. The excretion of most drugs into the mother´s milk is negligible;
timolol seems to be an exception, as it has been detected in milk after a single drop of 0.5% timolol (case reports [39]
and [40]). Interestingly, obstetricians widely prescribe oral beta-blockers to control hypertension during pregnancy,
apparently without any major problems, but it is known that systemically administered timolol is not able to reduce IOP
[38]. The peak concentration of topically administered eye drops in the systemic circulation is reached within 30-120
minutes after application. If possible, the drug administration should be scheduled to avoid the time when the mother is
suckling her child. However, there is no consensus as to the use of timolol; Lustgarten and Podos: “timolol should be
used with caution by nursing mothers”, Madadi and associates “this dose of timolol is unlikely to cause systemic side-
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effects in a healthy breastfed infant” [39, 40].
Oral carbonic anhydrase inhibitors (acetazolamide) at high doses have evoked birth defects in animals [41 - 43], but
there is  little  clinical  evidence in support  of  such an outcome in humans,  though a single case of  a sacrococcygeal
teratoma [44], transient renal tubular acidosis [45] and a single case of suspected congenital malformations [46] have
been described. There are no reports of fetal complications following topical use of carbonic anhydrase inhibitors in
pregnant women or abnormal reactions in breast-fed infants [37], though these compounds were found to retard the
body weight of dog pups.
All prostaglandin analogues have been classified by FDA into category C due to their capability to stimulate uterine
smooth muscle contraction, but they are considered a reasonable option during lactation [35]. They are excreted into
breast milk in animals, but it is not known whether this is also the case in humans [37].
Anticholinergics  are  also  classified  as  category  C  since  in  experimental  animals  they  have  been  shown  to  be
teratogenic and to cause adverse effects [37, 47].
Sympathomimetics  such  as  alpha-2-agonists  can  surprisingly  be  used  during  pregnancy  (category  B)  but  are
contraindicated during nursing as possible causing severe nervous system depression in breast- fed infants.
In conclusion, none of the anti-glaucoma drugs has been shown to be teratogenic in humans but on the other hand,
none can be said to be risk-free. In some cases, when necessary, even glaucoma surgery can be performed with caution,
preferably  after  the  first  trimester,  although,  anesthetics,  sedative  agents  and  antimetabolites  are  of  course  also
potentially  risky  for  the  fetus  [46].
In  addition,  mothers-to-be  may  also  require  other  ophthalmic  drugs,  e.g.  a  course  of  antibiotic  therapy  may be
required. Thomseth and associates (2015) published a nationwide cohort study on exposure to topical chloramphenicol
during  pregnancy  (966  372  births  1997  -  2011,  6024  women  exposed  to  topical  chloramphenicol  during  the  first
trimester)  to  evaluate  the  risk  of  congenital  malformations.  The  authors  found  no  association  with  the  use  of
chloramphenicol, in agreement with a previous study which analyzed the risk after systemic administration of the drug
[48].
1.4. Elderly People
The elderly constitutes another group of at-risk patients. Elderly patients often suffer from a number of diseases and
polypharmacy. In these subjects, the effects of ophthalmic medications on autonomic nervous system, as in the case of
vasoconstrictors  (tetrahydrozoline),  mydriatics  (phenylephrine,  cyclopentolate,  tropicamide),  anti-glaucoma  drugs
(dipivefrine,  brimonidine,  apraclonidine),  can  induce  unpleasant  sympathomimetic  adverse  effects.  Patients  treated
orally  with  adrenergic  beta-receptor  blocking  drugs  (“beta  blockers”)  are  at-  risk  of  adverse  cardiac  effects  if
ophthalmic timolol is dispensed. In some at-risk patients it is even recommended that ECG should be registered prior to
the initiation of ophthalmic treatment with timolol or betaoxol [11]. Even in apparently healthy subjects, adrenergic
beta-antagonists have induced marked bradycardia, even other arrhythmias and possibly also bronchoconstriction and
hypotension,  especially if  administered in combination with other  cardiovascular  or  psychoactive drugs.  Other  less
frequent  adverse  problems  are  central  effects  such  as  anxiety,  depression,  confusion,  hallucinations  and  sedation.
Topically  administered  timolol  eye  drops  are  not  the  only  ophthalmic  preparations  to  cause  severe  confusion;
scopolamine can also cause such episodes, especially in elderly people. Acetazolamide administered orally is another
ophthalmic therapy capable of triggering mental confusion.
Huber and co-workers reported a material from 8 685 nursing home residents with almost 90 000 drug prescriptions
(average  6.0  +/-  3.3  different  drugs)  [49].  Glaucoma  was  recorded  in  520  (6.0%)  of  the  residents.  The  authors
concluded  that  anti-glaucoma  pharmacotherapy  was  frequently  prescribed  in  the  context  of  polypharmacy.  Similar
observations with an even higher percentage (23%) were reported from Australia in a group of patients aged 75-84
years who were being treated with both topical and systemic beta-blockers [50]. In such a situation, the efficacy and
safety of local and systemic therapies are modified and harmful drug-drug interactions become possible. It is not known
whether ophthalmic beta-blockers can mask the symptoms of hypoglycemia induced by antidiabetic drugs, as is the case
with oral beta-blocker administration.
1.5. Other Adverse Effects
Ophthalmic preparations can induce local effects in tissue situated close to the eyes, for example coloring of cheek
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or eyelids and growth of eyelashes (prostaglandin derivatives). In addition to local allergic reactions, ophthalmic agents
can  also  cause  generalized  dermatological  reactions  including  toxic  epidermal  necrolysis,  anaphylaxis,  fixed  drug
eruption, lichenoid drug reaction and systemic contact dermatitis [51].
1.6. Adverse Ocular Effects Caused by Systemic Drugs
Many systemic drugs given as either acute or chronic therapy may cause ophthalmic adverse effects. This includes
drugs which directly influence the autonomic nervous systems, i.e. its adrenergic or cholinergic arms, or drugs which
are indicated in other diseases but have autonomic side- effects, e.g. antipsychotic or antidepressant drugs which may
antagonize the cholinergic system and thus increase intraocular pressure (IOP) especially when not in balance. This can
also be seen during treatments with MAO-inhibitors, anti-Parkinson drugs, some antihistamines and cytotoxic drugs. It
is  well  known  that  chronic  glucocorticoid  therapy  can  increase  IOP  and  promote  cataract  development.
Hydroxychloroquine and chloroquine, two drugs used for decades for the prevention of malaria and to treat rheumatic
and other autoimmune diseases, are irreversibly toxic to the retina [52]. Furthermore, the toxic effects of ethambutol on
the optic nerve may also be irreversible. The possibility has also been raised that nonsteroidal anti-inflammatory drugs
may  induce  visual  side-  effects  due  to  retinal  toxicity  [53].  Very  occasionally  bisphosphonate  therapy  has  been
associated with orbital inflammation [54]. Corneal epithelial changes can be induced by drugs in many pharmacological
classes; they occur as an accumulation of phospholipids, vortex keratopathy or crystalline epithelial precipitation and
blurred vision [55]. Toxic epidermal necrolysis and Stevens-Johnson Syndrome are both rare, acute, life-threatening
dermatologic disorders involving the skin and mucous membranes and occasionally also the eye [56]. Recently three
comprehensive reviews have been published on systemic drug therapy inducing ophthalmic adverse drug reactions [57 -
59].
CONCLUSION
One must remember that local ocular therapy involves high concentrations of drug molecules in a small volume, i.e.
one drop, and may cause marked, even dangerous systemic effects especially in newborns, small children and elderly
patients. Aged patients often suffer from a number of diseases and may therefore be receiving systemic medicines, i.e.
“polypharmacy”.  This  markedly  increases  the  risk  of  harmful  drug-drug  interactions  with  ophthalmological
preparations. The ophthalmologist should be aware of this possibility and carefully determine the patient’s drug history,
including so-called “natural  products”.  Even though the data presented here is  based on case reports,  the physician
should keep in mind that “my case might be one of the first”.
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